PRESENTATION
Q3 2024 — Presentation
Q3 2024PDF · 29 pages1.7 MB
Merck Q3 2024 Earnings October 31, 2024 -- 1 of 29 -- Agenda 2 Strategy and Business Update Rob Davis Chairman and Chief Executive Officer Question & Answer Session Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories -- 2 of 29 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 29 -- Strategy and Business Update Rob Davis Chairman and Chief Executive Officer -- 4 of 29 -- Delivered on our key strategic priorities in Q3 2024 Advanced the pipeline to meet patient unmet need Achieved strong commercial and financial performance Executed on strategic business development to augment pipeline Created long-term value for patients and shareholders 5 -- 5 of 29 -- 20,000 30,000 40,000 50,000 60,000 70,000 2022 2023 2024 Strong Q3 underlying performance1 6 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Merck does not exclude charges for certain upfront payments and income from certain receipts related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Third quarter of 2024 includes a net charge of $0.79 per share for such items. Full year non-GAAP outlook for 2024 and full year reported results for 2023 and 2022 include $1.05, $6.21 and $0.22 per share of such net charges, respectively. 3. GAAP EPS $1.24. $16.7B +4% +7% ex-Exchange Q3 Worldwide Sales Q3 Non-GAAP EPS3 $5.37 Full Year Sales Full Year Non-GAAP EPS2 $59.3B +22% $60.1B +1% 2022 2023 2024 $1.51 $7.48 GUIDANCE RANGE $63.6B - $64.1B +6% - +7% GUIDANCE RANGE $7.72 - $7.77 $1.57 -- 6 of 29 -- Advancing and broadening our diverse pipeline 7 Infectious Disease Presented positive Phase 2 islatravir and lenacapavir combination data for HIV Vaccines Presented positive Phase 2b/3 results for clesrovimab, & ACIP voted to expand recommendation for CAPVAXIVE to 50-64 Immunology Presented positive Phase 2 maintenance data for tulisokibart in UC and CD Oncology Presented data for 10 investigational or approved medicines at ESMO Business Development Acquired CN201 (MK-1045) from Curon with potential applications in oncology and immunology -- 7 of 29 -- Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer -- 8 of 29 -- Strong Q3 worldwide sales growth 9 Merck WORLDWIDE SALES1 $16.7B+4% growth +7% ex-exchange 2 $14.9B +5% growth +8% ex-exchange2 Human Health $1.5B +6% growth +11% ex-exchange2 Animal Health 1. Worldwide Sales includes Other Revenue. 2. ~2 percentage points of the negative impact of foreign exchange for Worldwide Sales, Human Health and Animal Health, was due to devaluation of the Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. -- 9 of 29 -- Oncology: KEYTRUDA continues to drive exceptional growth 10 Growth rates exclude the impact of foreign exchange. 1. ~3 percentage point negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. • KEYTRUDA sales of $7.4B increased 21%1 year-over-year, driven by uptake in earlier stage cancers and continued robust global demand from metastatic indications – In the U.S., growth reflects increased use in resectable NSCLC, as well as uptake from KN-A39 in advanced urothelial cancer – Ex-U.S. growth reflects continued uptake in earlier stage cancers, including high-risk, early- stage TNBC, as well as demand from metastatic indications $4.2B +20% $3.4B +31% $5.3B +30% 3Q22 3Q23 3Q24 $5.4B +26% $7.4B +21% $6.3B +17% -- 10 of 29 -- Oncology: Updates across broad portfolio • Lynparza 1 sales grew 13%, driven primarily by increased global demand • Lenvima 2 sales declined 4%, driven primarily by timing of shipments last year • WELIREG sales more than doubled, driven by increased uptake in certain patients with previously treated advanced RCC $181M +15% $151M +57% 11 Growth rates exclude the impact of foreign exchange. 1. In collaboration with AstraZeneca 2. In collaboration with Eisai 3Q22 3Q23 3Q24 $299M +6% $284M +23% $337M +13% 3Q22 3Q23 3Q24 $260M +30% $202M +11% $251M -4% 3Q22 3Q23 3Q24 $54M +43%$38M $139M +157% -- 11 of 29 -- 3Q22 3Q23 3Q24 $1.7B +40% 3Q22 3Q23 3Q24 $2.6B +16% Vaccines: Broad vaccines portfolio having significant patient impact 12 • GARDASIL sales of $2.3B decreased 10% year-over-year, driven by a decline in China – In the U.S., sales benefitted from CDC purchasing patterns, as well as price and demand – Ex-U.S. sales increased by double digits in almost every region driven by robust demand • VAXNEUVANCE sales of $239M grew 13%, driven by ongoing launches in ex-U.S. markets • Recent launch of CAPVAXIVE off to an encouraging start Growth rates exclude the impact of foreign exchange. $2.3B -10% $2.3B +20% $16M $214M $239M +13% -- 12 of 29 -- Cardiovascular: Continued successful launch of WINREVAIR 13 $1.7B +40% $1.9B +27% $2.5B +4% Q3 sales of $149M Payors Prescribers Patients • Achieved coverage for ~60% of lives since launch • Many payors established coverage policies consistent with the label or STELLAR criteria • ~1,700 new patients prescribed in the quarter • >3,700 total patients prescribed since launch • ~80% of prescribed patients receive commercial product • >2,600 commercial patients started treatment since launch • ~10,000 total prescriptions written since launch • Nearly 800 physicians have written at least one prescription since launch • Most prescribers are from large academic centers or larger private practices • Physicians continue to prioritize the sickest PAH patients Positive initial feedback following recent EU approval -- 13 of 29 -- Animal Health: Strong growth across companion animal and livestock 14 • Animal Health sales increased 11% 1 to $1.5B – Companion Animal grew 17%, driven by uptake from new product launches and price – Livestock sales grew 7%, driven by higher demand for poultry and swine products, the inclusion of sales from the recently expanded aqua portfolio, and price 3Q22 3Q23 3Q24 $1.4B +4% $1.4B +2% $1.5B +11% Growth rates exclude the impact of foreign exchange. 1. ~2 percentage point negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. -- 14 of 29 -- Q3 2024 non-GAAP financial results summary1 Q3 2024 Q3 2023 Change Change Ex-FX Sales $16.7 $16.0 +4% +7% Non-GAAP Gross Margin 80.5% 77.0% +3.5pts +3.4pts Non-GAAP Operating Expenses $8.5 $5.8 +48% +49% Non-GAAP Tax Rate 21.9% 15.0% +6.9pts N/A Non-GAAP EPS2,3 $1.57 $2.13 -26% -23% $ in billions, except EPS amounts 15 1. Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q3 2024 includes a net charge of $0.79 per share for the EyeBio (including milestone), Curon and Daiichi Sankyo transactions. 3. Q3 2024 GAAP EPS of $1.24 -- 15 of 29 -- Updated 2024 financial outlook 1. Guidance does not assume any additional significant potential business development transactions. 16 Prior Guidance Updated Guidance Key Assumptions Revenue $63.4B to $64.4B $63.6B to $64.1B • Assumes ~3 percentage point FX headwind (no change) • Implies growth of 6% to 7% Non-GAAP Gross Margin Rate ~81.0% ~81.0% Non-GAAP Operating Expenses1 $26.8B to $27.6B $27.8B to $28.3B • Now includes $750 million one-time charge related to the asset acquisition from Curon Other (Income) / Expense ~$350M of expense ~$100M of expense • Now includes $170 million payment from Daiichi Sankyo Tax Rate ~15.5% to 16.5% ~16.0% to 17.0% • Now includes unfavorable impact related to the Curon transaction Shares Outstanding ~2.54B ~2.54B • Assumes modest share repurchase (no change) Non-GAAP EPS $7.94 to $8.04 $7.72 to $7.77 • Now includes one-time $0.29 charge related to the Curon transaction, and $0.05 benefit related to payment from Daiichi Sankyo • Assumes ~$0.30 FX headwind in 2024 (no change) -- 16 of 29 -- 17 Continue to invest in the pipeline and business while augmenting the pipeline with value-enhancing business development $3.1 $0.8 $2.0 $3.2 $0.4 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Q3 Spend ($ in billions) 1 1. Reflects quarter spend 2. Reflects R&D excluding Business Development Remain committed to balanced capital allocation strategy Capital allocation order of priority 2 -- 17 of 29 -- Research Update Dr. Dean Li President, Merck Research Laboratories -- 18 of 29 -- Important updates across our vaccines, immunization and infectious disease programs 19 RSV • CDC’s ACIP voted in favor of expanding the age-based recommendation for CAPVAXIVE to individuals 50-64 years of age • Decision expands on initial ACIP recommendation for individuals age 65+ • Presented results at IDWeek from Phase 2b/3 trial evaluating clesrovimab, an investigational RSV preventative monoclonal antibody for infants entering their first RSV season • Clesrovimab significantly reduced incidence of RSV through 5 months, the primary endpoint, and hospitalizations associated with RSV infection through 5 months, the secondary endpoint • If approved, clesrovimab would be the first and only immunization designed to provide infants with protection for full 6-month RSV season with convenience of one dose, regardless of weight Pneumococcal HIV • Presented results at IDWeek from Phase 2 trial evaluating combination of islatravir and lenacapavir1 as once-weekly oral treatment option for people living with HIV • 48-Week results build on positive 24-Week data previously presented 1. In collaboration with Gilead -- 19 of 29 -- Renal Head & Neck Skin Extensive ongoing, Phase 3 clinical development program for KEYTRUDA-based regimens in earlier stages of cancer1 20 FDA approved indications Demonstrated OS benefit2 4 9 Breast Gynecological Liver Lung Bladder KN-091 KN-671 KV-006 KN-937 LEAP-012 KN-564 LITESPARK-022 KN-057 KN-123 KN-689 KN-522 KN-756 KN-054 KN-716 KN-629 KN-A18 1. Operable and/or no/limited spread to other parts of the body 2. Achieved OS in cancer type (not all currently labeled) 3. INTerpath-007 in csCC Ph 2/3 development Announced positive data for: Esophageal KN-975 KL-012 KL-013 TroFuse-019 INTerpath-002 INTerpath-009 KN-866 KN-676 KN-905 KN-992 KN-B15 INTerpath-001 INTerpath-007 3 KN-242 TroFuse-012 KN-689 KN-123 KN-756 LEAP-012 -- 20 of 29 -- Recent Approvals ESMO 21 Broadening the impact of KEYTRUDA U.S. • KEYNOTE-483: FDA approved KEYTRUDA in combination with pemetrexed and platinum chemotherapy for 1L treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma Europe • KEYNOTE-A39: EC approved KEYTRUDA in combination with Padcev for 1L treatment of adult patients with unresectable or metastatic urothelial carcinoma • KEYNOTE-868: EC approved KEYTRUDA in combination with carboplatin and paclitaxel for 1L treatment of certain patients with primary advanced or recurrent endometrial carcinoma • KEYNOTE-A18: EC approved KEYTRUDA in combination with chemoradiotherapy for treatment of certain patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer Japan • KEYNOTE-052: MHLW approved KEYTRUDA for treatment of patients with radically unresectable urothelial carcinoma not eligible for any platinum-containing chemotherapy • KEYNOTE-671: MHLW approved KEYTRUDA for neoadjuvant and adjuvant treatment of certain patients with resectable NSCLC • KEYNOTE-A39: MHLW approved KEYTRUDA in combination with Padcev for 1L treatment of patients with radically unresectable urothelial carcinoma • Three presentations for KEYTRUDA showcased during Presidential Symposium sessions: • OS data from KEYNOTE-522 in patients with high-risk early-stage triple-negative breast cancer • OS data from KEYNOTE-A18 in patients with newly diagnosed, high- risk, locally advanced cervical cancer • 10-year follow-up OS data from KEYNOTE-006 showing long-term benefit over ipilimumab in patients with advanced melanoma -- 21 of 29 -- Continuing to advance our broader oncology program with BD 22 Exelixis Daiichi Sankyo • Announced clinical development collaboration with Exelixis to evaluate investigational tyrosine kinase inhibitor, zanzalintinib in combination with: • KEYTRUDA for treatment of patients with HNSCC • WELIREG for treatment of patients with RCC • Initiated Phase 3 IDeate-Lung02 trial evaluating I-DXd, a B7-H3 directed antibody drug conjugate, for treatment of patients with relapsed SCLC • Expanded collaboration agreement to evaluate combination of I-DXd with MK-6070, an investigational DLL3 targeting T-cell engager -- 22 of 29 -- Executing on our broader pipeline 23 Immunology • Received EC approval for WINREVAIR which has potential to transform the treatment journey for patients with PAH • Presented 50-week efficacy and safety data for tulisokibart, a TL1A inhibitor, from Phase 2 ARTEMIS-UC and APOLLO-CD studies in ulcerative colitis and Crohn’s disease at UEG Week Congress • Results reinforce potential to help patients achieve long-term clinical remission Cardiometabolic Ophthalmology • Initiated Phase 2b/3 BRUNELLO trial for MK-3000, an investigational tetravalent tri- specific Wnt antibody, for treatment of diabetic macular edema -- 23 of 29 -- Q&A Rob Davis Chairman & Chief Executive Officer Caroline Litchfield Chief Financial Officer Dr. Dean Li President, Merck Research Laboratories Peter Dannenbaum Senior Vice President, Investor Relations -- 24 of 29 -- Appendix 25 -- 25 of 29 -- Q3 2024 GAAP financial results summary 26 Q3 2024 Q3 2023 Change Change Ex-FX Sales $16.7 $16.0 +4% +7% Operating Expenses $8.6 $5.8 +47% +49% Tax Rate 22.7% 15.5% +7.2pts N/A GAAP EPS1 $1.24 $1.86 -33% -30% $ in billions, EPS amounts 1. 3Q24 GAAP results include a net charge of $0.79 per share for the EyeBio (including milestone), Curon and Daiichi Sankyo transactions -- 26 of 29 -- $11.7 $3.4 $7.7 $10.1 $1.2 $0 $3 $6 $9 $12 $15 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation: Trailing twelve months ~$ 20B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$11B in the U.S. Billions Over the past 12 months Capital investments 2024 to 2028 Commitment to the dividend 27 Well-positioned balance sheet with capacity to fund additional value-enhancing business development opportunities Order of priority 1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow 3. Previous values presented at 2Q24 earnings corrected by the company 2 1 E -- 27 of 29 -- Driving value for patients and shareholders by progressing our pipeline • In the U.S., the FDA approved: o KEYTRUDA in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma based on IND.227/KN-483 • In the EU, the EC approved: o KEYTRUDA in combination with carboplatin and paclitaxel followed by KEYTRUDA as a single agent, for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy based on NRG-GY018/KN-868 o KEYTRUDA in combination with chemoradiotherapy for the treatment of FIGO 2014 stage III-IVA locally advanced cervical cancer in adults who have not received prior definitive therapy based on KN-A18 o KEYTRUDA in combination with Padcev for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma based on KN- A39/EV-302 1 o WINREVAIR in combination with other PAH therapies for the treatment of PAH in adult patients with WHO FC II to III to increase exercise capacity based on STELLAR • In Japan, the MHLW approved: o KEYTRUDA in combination with chemotherapy as a neoadjuvant treatment, then continued as monotherapy as an adjuvant treatment, for patients with NSCLC based on KN-671 o KEYTRUDA in combination with Padcev for the first-line treatment of patients with radically unresectable urothelial carcinoma based on KN-A39/EV-302 1 o KEYTRUDA monotherapy in patients with radically unresectable urothelial carcinoma who are not eligible for any platinum-containing chemotherapy based on KN-052 30 1. Trial conducted in collaboration with Seagen (now Pfizer) and Astellas 2. In collaboration with Daiichi Sankyo 3. In collaboration with Kelun-Biotech 4. In collaboration with Orion 5. In collaboration with Moderna 6. In partnership with Gilead 7. On FDA partial clinical hold for higher doses than those used in current clinical trials Announced: • Phase 3 KN-689 trial evaluating KEYTRUDA met its primary endpoint of event-free survival as perioperative treatment regimen in patients with resected, LA-HNSCC • Phase 3 HERTHENA-Lung02 trial evaluating patritumab deruxtecan (HER3 ADC)2 met its primary endpoint and demonstrated statistically significant improvement in progression-free survival in patients with locally advanced or metastatic EGFR- mutated NSCLC Presented data from: • Diverse vaccines and infectious disease portfolio at IDWeek, including positive results from the Phase 2b/3 study evaluating clesrovimab, data from the Phase 3 STRIDE-8 trial evaluating CAPVAXIVE in adults 18-64 years of age at increased risk of pneumococcal disease, and data from the Phase 2 study evaluating a once-weekly oral combination regimen of islatravir and lenacapavir for treatment of people with HIV-1 infection • Phase 2 studies evaluating tulisokibart, an investigational humanized monoclonal antibody directed to TL1A, in ulcerative colitis and Crohn’s disease at UEG Week • Broad oncology portfolio at ESMO, including for KEYTRUDA, WELIREG, Lenvima, Lynparza, patritumab deruxtecan (HER3 ADC)2, ifinatamab deruxtecan (B7-H3 ADC)2, sacituzumab tirumotecan (TROP2 ADC)3, and opevsostat (CYP11A1 inhibitor)4 • Phase 2 IDeate-Lung01 study at the World Conference on Lung Cancer showing ifinatamab deruxtecan (B7-H3 ADC)2 in SCLC Initiated Phase 3 trials evaluating: • V9405, ifinatamab deruxtecan (B7-H3 ADC)2, bomedemstat (LSD1 inhibitor), zilovertamab vedotin (ROR1 ADC), MK-3000 (Wnt agonist), and the fixed-dose combination of islatravir and lenacapavir (HIV1) 6,7 Key data & clinical advancements since the last earnings call: Key regulatory milestones since the last earnings call: -- 28 of 29 -- Broad and innovative pipeline to address significant unmet medical needs Phase 2 Phase 3 Under regulatory review V181 Dengue Virus Vaccines Infectious disease MK-8527 HIV-1 Pre-Exposure Prophylaxis MK-8591B (islatravir+MK-8507)1 HIV-1 infection MK-2060 Thrombosis MK-5475 PH-COPD MK-6024 (efinopegdutide) NASH WINREVAIR (MK-7962) Pulmonary Hypertension due to Left Heart Disease Cardiometabolic MK-4280A (favezelimab + pembrolizumab) Bladder CRC cSCC Endometrial Esophageal Melanoma RCC MK-5890 (boserolimab) Neoplasm Malignant MK-5909 (raludotatug deruxtecan)4 Ovarian WELIREG (MK-6482) Endometrial Esophageal HCC Prostate Rare Cancers MK-2400 (ifinatamab deruxtecan)4 Biliary Bladder Breast Cervical CRC Endometrial Esophageal HNSCC Ovarian MK-2870 (sacituzumab tirumotecan)5 Biliary CRC Neoplasm Malignant Pancreatic KEYTRUDA (MK-3475) Advanced Solid Tumors Prostate MK-4280 (favezelimab) NSCLC LYNPARZA (MK-7339)6 Advanced Solid Tumors MK-7684A (vibostolimab +pembrolizumab) Bladder CRC Endometrial Melanoma Ovarian Prostate RCC V940 7 Bladder cSCC RCC MK-1022 (patritumab deruxtecan)4 Bladder Cervical Endometrial Esophageal Gastric HNSCC Melanoma Ovarian Pancreas Prostate MK-1308 (quavonlimab) NSCLC MK-1308A (quavonlimab +pembrolizumab) CRC MK-3475A (pembrolizumab + hyaluronidase) cSCC Heme 1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials 3 Available in the US under EUA 4 In collaboration with Daiichi Sankyo 5In collaboration with Kelun-Biotech 6 In collaboration with AstraZeneca 7In collaboration with Moderna 8 In collaboration with Gilead 9 Developed under an agreement with Ridgeback Bio 10In collaboration with Orion 11In collaboration with Eisai 12Program is in Phase 2/3 study 13 FDA issued CRL in June 2024 MK-6194 Vitiligo Immunology Oncology Infectious disease Oncology MK-1022 (patritumab deruxtecan)4 NSCLC (EU) MK-1026 (nemtabrutinib) Hematological Malignancies MK-1084 NSCLC MK-1308A (quavonlimab +pembrolizumab) RCC MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan)4 SCLC MK-2870 (sacituzumab tirumotecan)5 Breast Cervical Endometrial Gastric NSCLC MK-3543 (bomedemstat) Myeloproliferative Disorders KEYTRUDA (MK-3475) Hepatocellular (EU) Ovarian SCLC MK-3475A (pembrolizumab +hyaluronidase) NSCLC MK-4280A (favezelimab +pembrolizumab) Hematological Malignancies MK-5684 (opevesostat)10 Prostate LYNPARZA (MK-7339)6 NSCLC SCLC LENVIMA (MK-7902)11 Esophageal Gastric MK-7684A (vibostolimab +pembrolizumab) NSCLC V940 7 Melanoma NSCLC MK-8591A (doravirine+islatravir)2 HIV-1 Infection MK-8591D (islatravir+lenacapavir)2,8 HIV-1 infection LAGEVRIO (MK-4482)3,9 COVID-19 antiviral Immunization MK-1654 (clesrovimab) Respiratory Syncytial Virus (RSV) Cardiometabolic MK-7240 (tulisokibart) Ulcerative Colitis Immunology MK-0616 (enlicitide decanoate) Hypercholesterolemia As of October 31, 2024 Oncology KEYTRUDA (MK-3475) Endometrial Carcinoma (JPN) Cervical (JPN) Mesothelioma (EU, JPN) MK-1022 (patritumab deruxtecan)4, 13 NSCLC (US) WELIREG (MK-6482) Advanced RCC (EU, JPN) Certain VHL tumors (EU, JPN) Vaccines CAPVAXIVE (V116) Pneumococcal conjugate vaccine, adult (EU, JPN) MK-3000 12 Diabetic macular edema Ophthalmology -- 29 of 29 --